Naveen Krishnan

Naveen Krishnan currently serves as a Board Member at Accent Therapeutics, Inc. and the Senior Vice President & Managing Director at Mirae Asset Capital Life Science, leading the firm’s U.S. operations. Previously, Naveen held the position of Senior Director of Venture Investment at Leaps by Bayer, where minority equity investments in various healthcare sectors were facilitated. Additionally, Naveen has served on the boards of several companies, including Lyterian Therapeutics, Bloom Science, Woebot Health, Ada Health, Cellino, Edifice Health, and Azitra Inc., demonstrating a strong focus on innovative healthcare solutions spanning gene therapy, digital health, and chronic inflammation. Naveen holds an MD from the Geisel School of Medicine at Dartmouth, an MPhil in Public Health from the University of Cambridge, and a BS in Brain and Cognitive Sciences from the Massachusetts Institute of Technology.